Descriptive only
Death by suicide
Overweight or obesity without diabetes (adults)
longest follow-upRecorded harmsEach dose separatelyHazard ratio (from event counts)
15
Randomized trials
33
Treatments
5,792
Participants
0
Events
In plain language
No network meta-analysis was fitted here. The protocol requires at least two trials forming a connected network; this outcome has 15 trials. The trial data below are shown as reported.
Network of trials
Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
Comparability of the trials
Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.
- NoteOutcome assessment, time point: selected time points span 16 to 76 weeks
- NoteOutcome assessment, analysis set: mixed: randomized 3, randomized;safety 1, safety 11
- NoteOutcome assessment, definition: mixed: C-SSRS post baseline category 1, deaths 1, not stated 13
- NoteOutcome assessment, intercurrent events (discontinuation): mixed: not stated 14, while_on_treatment 1
- NoteOutcome assessment, intercurrent events (rescue): mixed: not stated 14, treatment_policy 1
- NoteRisk of bias, blinding: mixed: double_blind 14, open_label 1
- NoteData handling, input conversions: arms_combined 3
| Trial | time weeks | analysis set | definition | instrument | adjudicated | proportion method | intercurrent events (discontinuation) | intercurrent events (rescue) | blinding | funding | start year | Eligibility |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04081337 | 22 | randomized;safety | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2020 | age 18 to 60; BMI 30 to 45; no diabetes; at least one metabolic impairment |
| SURMOUNT-5 | 72 | safety | not stated | not stated | not stated | not stated | not stated | not stated | open_label | industry | 2023 | adults; BMI 30 or more, or 27 with complication; no diabetes |
| STEP 1 | 75 | safety | not stated | not stated | not stated | not stated | while_on_treatment | treatment_policy | double_blind | industry | 2018 | adults; BMI 30 or more, or 27 or more with a weight related condition; no diabetes; HbA1c below 6.5 percent |
| NCT05579977 | 28 | safety | C-SSRS post baseline category | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2022 | age 18 to 75; T2D cohort on metformin, HbA1c 7.0 to 10.0, BMI 23 or more; obesity cohort BMI 30 or more without diabetes |
| NCT02075281 | 26 | randomized | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2014 | age 18 to 64 years; BMI 30 to 42, or 27 to 30 with comorbidity; FPG below 7 mmol/L; HbA1c 6.5 percent or less; no diabetes |
| Dapalost | 24 | safety | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2014 | age 18 to 70; BMI 30 to 45 kg/m2; no diabetes |
| STABLE Wt Loss | 60 | randomized | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2022 | age 18 to 70; BMI 30 or more, or 27 or more with comorbidity; no diabetes; HbA1c 6.5 percent or less |
| NCT04881760 | 52 | safety | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2021 | 18 to 75 years; BMI 30 or more, or 27 to less than 30 with weight related complication; no type 2 diabetes |
| DREAM | 16 | randomized | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2023 | age 18 to 75; BMI 30 or more; no diabetes, HbA1c below 48 mmol/mol |
| SURMOUNT-3 | 76 | safety | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2021 | age 18 or older; BMI 30 or more, or 27 or more with comorbidity; no diabetes; at least 5 percent loss in lead in |
| NCT06250946 | 36 | safety | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2024 | age 18 to 65; BMI 28 to 40; no diabetes, HbA1c below 6.5 percent |
| NCT01557166 | 34 | safety | deaths | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2012 | age 18 to 64; BMI 30 or more; AHI 15 or more; no diabetes; unable or unwilling to use CPAP |
| NCT06569355 | 18 | safety | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2023 | age 18 to 75; BMI 28 or more, or 24 to 28 with comorbidity; no diabetes |
| NCT06256562 | 33 | safety | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2023 | age 18 to 75; BMI 24 to <28 kg/m2 with comorbidity or 28 or more (Chinese criteria); no diabetes |
| S003017 | 52.14 | safety | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2019 | age 20 to 65; BMI above 35; 12 to 36 months after bariatric surgery with suboptimal stable weight loss or regain |
Trial data
What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio (from event counts) on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.
| Trial | Arm | Treatment | Week | Data | Value | SE | Events / N | Flags | Source |
|---|---|---|---|---|---|---|---|---|---|
| NCT04081337 | A1 | PLACEBO | 22 | arm, events | 0 / 28 | R0004227:Supplement Table S1 | |||
| NCT04081337 | A2 | TIRZ_SC_15MG_QW | 22 | arm, events | 0 / 27 | registry:adverse_events | |||
| SURMOUNT-5 | A1 | TIRZ_SC_MTD_QW | 72 | arm, events | 0 / 375 | registry:adverse_events | |||
| SURMOUNT-5 | A2 | SEMA_SC_MTD_1p7-2p4_QW | 72 | arm, events | 0 / 376 | registry:adverse_events | |||
| STEP 1 | A1 | SEMA_SC_2p4MG_QW | 75 | arm, events | 0 / 1,306 | R0023399:Table 3 | |||
| STEP 1 | A2 | PLACEBO | 75 | arm, events | 0 / 655 | R0023399:Table 3 | |||
| NCT05579977 | A10 | LOTI_PO_140MG_QD | 28 | arm, events | 0 / 64 | registry:outcomes | |||
| NCT05579977 | A11+A12 | LOTI_PO_200MG_QD | 28 | arm, events | 0 / 131 | arms_combined | registry:outcomes | ||
| NCT05579977 | A13 | LOTI_PO_260MG_QD | 28 | arm, events | 0 / 64 | registry:outcomes | |||
| NCT05579977 | A8 | PLACEBO | 28 | arm, events | 0 / 64 | registry:outcomes | |||
| NCT05579977 | A9 | LOTI_PO_80MG_QD | 28 | arm, events | 0 / 66 | registry:outcomes | |||
| NCT02075281 | A1 | PLACEBO | 26 | arm, events | 0 / 60 | R0011218:Figure S2 | |||
| NCT02075281 | A2 | EFPE_SC_4MG_QW | 26 | arm, events | 0 / 59 | R0011218:Figure S2 | |||
| NCT02075281 | A3 | EFPE_SC_6MG_QW | 26 | arm, events | 0 / 59 | R0011218:Figure S2 | |||
| NCT02075281 | A4 | EFPE_SC_6MG_Q2W | 26 | arm, events | 0 / 59 | R0011218:Figure S2 | |||
| NCT02075281 | A5 | EFPE_SC_8MG_Q2W | 26 | arm, events | 0 / 60 | R0011218:Figure S2 | |||
| Dapalost | A1 | EXENER_SC_2-10MG_QW | 24 | arm, events | 0 / 25 | R0025627:Table 3 | |||
| Dapalost | A2 | PLACEBO | 24 | arm, events | 0 / 25 | R0025627:Table 3 | |||
| STABLE Wt Loss | A1 | SEMA_SC_2p4MG_QW | 60 | arm, events | 0 / 72 | R0013679:Table 4 | |||
| STABLE Wt Loss | A2 | PLACEBO | 60 | arm, events | 0 / 48 | R0013679:Table 4 | |||
| NCT04881760 | A1 | PLACEBO | 52 | arm, events | 0 / 70 | registry:adverse_events | |||
| NCT04881760 | A2 | RETA_SC_1MG_QW | 52 | arm, events | 0 / 69 | registry:adverse_events | |||
| NCT04881760 | A3 | RETA_SC_4MG_QW | 52 | arm, events | 0 / 33 | registry:adverse_events | |||
| NCT04881760 | A5+A6 | RETA_SC_8MG_QW | 52 | arm, events | 0 / 70 | arms_combined | registry:adverse_events | ||
| NCT04881760 | A7 | RETA_SC_12MG_QW | 52 | arm, events | 0 / 62 | registry:adverse_events | |||
| DREAM | A1 | PLACEBO | 16 | arm, events | 0 / 18 | R0011013:Table 3 | |||
| DREAM | A2 | DAPIGL_SC_4MG_QW | 16 | arm, events | 0 / 18 | R0011013:Table 3 | |||
| DREAM | A3 | DAPIGL_SC_6MG_QW | 16 | arm, events | 0 / 18 | R0011013:Table 3 | |||
| SURMOUNT-3 | A1 | TIRZ_SC_MTD_QW | 76 | arm, events | 0 / 287 | R0007405:Results | |||
| SURMOUNT-3 | A2 | PLACEBO | 76 | arm, events | 0 / 292 | R0007405:Results | |||
| NCT06250946 | A1 | PLACEBO | 36 | arm, events | 0 / 46 | R0001289:Table 6 | |||
| NCT06250946 | A2 | HRS7535_PO_30MG_QD | 36 | arm, events | 0 / 48 | R0001289:Table 6 | |||
| NCT06250946 | A3 | HRS7535_PO_60MG_QD | 36 | arm, events | 0 / 47 | R0001289:Table 6 | |||
| NCT06250946 | A4 | HRS7535_PO_120MG_QD | 36 | arm, events | 0 / 46 | R0001289:Table 6 | |||
| NCT06250946 | A5 | HRS7535_PO_180MG_QD | 36 | arm, events | 0 / 48 | R0001289:Table 6 | |||
| NCT01557166 | A1 | LIRA_SC_3p0MG_QD | 34 | arm, events | 0 / 180 | R0026203:Results | |||
| NCT01557166 | A2 | PLACEBO | 34 | arm, events | 0 / 179 | R0026203:Results | |||
| NCT06569355 | A1 | VCT220_PO_80MG_QD | 18 | arm, events | 0 / 65 | R0001121:Results | |||
| NCT06569355 | A2 | VCT220_PO_120MG_QD | 18 | arm, events | 0 / 62 | R0001121:Results | |||
| NCT06569355 | A3+A4 | VCT220_PO_160MG_QD | 18 | arm, events | 0 / 62 | arms_combined | R0001121:Results | ||
| NCT06569355 | A5 | PLACEBO | 18 | arm, events | 0 / 61 | R0001121:Results | |||
| NCT06256562 | A1 | BOFANG_SC_12MG_Q2W | 33 | arm, events | 0 / 52 | R0002409:Table 3 | |||
| NCT06256562 | A2 | BOFANG_SC_18MG_Q2W | 33 | arm, events | 0 / 53 | R0002409:Table 3 | |||
| NCT06256562 | A3 | BOFANG_SC_24MG_Q2W | 33 | arm, events | 0 / 52 | R0002409:Table 3 | |||
| NCT06256562 | A4 | BOFANG_SC_48MG_Q2W | 33 | arm, events | 0 / 64 | R0002409:Table 3 | |||
| NCT06256562 | A5 | BOFANG_SC_24MG_QW | 33 | arm, events | 0 / 53 | R0002409:Table 3 | |||
| NCT06256562 | A6 | PLACEBO | 33 | arm, events | 0 / 66 | R0002409:Table 3 | |||
| S003017 | A1 | LIRA_SC_3p0MG_QD | 52.14 | arm, events | 0 / 24 | R0016758:Discussion | |||
| S003017 | A2 | PLACEBO | 52.14 | arm, events | 0 / 24 | R0016758:Discussion |
Rerun this analysis yourself
Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.